News

As part of the management transition plan, Archemix also announced that the current president and interim CEO Duncan Higgons has accepted a position with another private biotechnology company

D-Pharm plans to initiate the trial later in 2009 following FDA review of the investigational new drug (IND) application and special protocol assessment (SPA). Recently, D-Pharm also obtained

The Phase I trial is a multi-center, open-label dose escalation study designed to evaluate the safety and tolerability of EC0489 in patients with refractory or metastatic cancer who

According to Medtronic, Attain Ability has the thinnest lead body of any left-heart lead currently available, providing physicians with a tool to deliver therapy directly to hard-to-reach areas

BioElectronics intends to file 510(k) premarket notification for the indication of reducing menstrual pain symptoms with the FDA by the end of May 2009. In the initial pilot

The approval was supported by two placebo-controlled Phase III clinical studies comparing Fanapt to placebo and active control in patients with schizophrenia, as well as safety data from

The Matrix IIb clinical trial which has now completed recruitment is a prospective, randomized, double-blind, placebo-controlled study that screened approximately 285 patients at 30 US medical centers and

The company also received tentative approval on the 500mg tablets and expects to receive final approval on August 3, 2009, upon expiration of the 180-day exclusivity period. Abbott

This large Phase I trial was a randomized, double-blind, placebo-controlled single dose study and comprised 64 healthy adult males, 48 of whom received ErepoXen while 16 received a